Evidence map›Paper›PMID 31197461›Full record

ArticleCancer immunology, immunotherapy : CII2019

Clinicopathological implications of TIM3

Jinpeng Zhou, Yang Jiang, Haiying Zhang, Lian Chen, Peng Luo, Long Li, Junshuang Zhao, Fei Lv, Dan Zou, Ye Zhang and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy.Journal of cancer research and clinical oncology · 2021
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jinpeng ZhouDepartment of Neurosurgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China.ORCID http://orcid.org/0000-0002-8915-9039
Yang JiangDepartment of Neurosurgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China.
Haiying ZhangInternational Education College, Liaoning University of Traditional Chinese Medicine, No. 79, Chongshan East Road, Huanggu District, Shenyang, 110032, China.
Lian ChenDepartment of Neurosurgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China.
Peng LuoDepartment of Neurosurgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China.
Long LiDepartment of Neurosurgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China.
Junshuang ZhaoDepartment of Neurosurgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China.
Fei LvThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China.
Dan ZouThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China.
Ye ZhangThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China. yzhang21@cmu.edu.cn.
Zhitao JingDepartment of Neurosurgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, China. jingzhitao@hotmail.com.
First Hospital of China Medical University · CNLiaoning University of Traditional Chinese Medicine · CNShanghai Chest Hospital · CN

Funding

Fund for Scientific Research of The First Hospital Of China Medical University FHCMU- FSRLiaoning Province Natural Science Foundation 20170541022National Natural Science Foundation of China 30901736National Natural Science Foundation of China 81101917National Natural Science Foundation of China 81270036Science and Technology Plan Project of Shenyang City 18-014-4-11the Plan to Focus on Research and Development from Science and Technology project of Liaoning Province 2017225029
6 · The paper itself

Abstract

Chordoma is difficult to eradicate due to high local recurrence rates. The immune microenvironment is closely associated with tumor prognosis; however, its role in skull base chordoma is unknown. The expression of Galectin-9 (Gal9) and tumor-infiltrating lymphocyte (TIL) markers was assessed by immunohistochemistry. Kaplan-Meier and multivariate Cox analyses were used to assessing local recurrence-free survival (LRFS) and overall survival (OS) of patients. MiR-455-5p was identified as a regulator of Gal9 expression. Immunopositivity for Gal9 was associated with tumor invasion (p = 0.019), Karnofsky performance status (KPS) score (p = 0.017), and total TIL count (p < 0.001); downregulation of miR-455-5p was correlated with tumor invasion (p = 0.017) and poor prognosis; and the T-cell immunoglobulin and mucin-domain 3 (TIM3)

Indexed as

AdolescentAdultAgedChildChordomaDisease-Free SurvivalFemaleFollow-Up StudiesGalectinsGene Expression Regulation, NeoplasticHepatitis A Virus Cellular Receptor 2HumansLymphocyte CountLymphocytes, Tumor-InfiltratingMaleMicroRNAsGalectinsHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2LGALS9 protein, humanMicroRNAsMIRN455 microRNA, humanCD8FOXp3Galectin–9miR-455-5pSkull base chordomaTIM3

Identifiers

PMID31197461
PMCPMC11028388
OpenAlexW2949663713

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.